posted
ENCY approved in EUROPE 42%+++ in revenue coming its oversold and way underpriced. MYOG a company that gave up PAH rights and also are working on similar drug but their is not even close to being approved Here's some DD The approval allows the company to sell 100 milligram tablets of Thelin in all 25 member states of the European Union. UBS gave over easy 45% revenue profit. THIS STOCK CAN EXPLOAD HUGE MONDAY .ENCY $3.93 closed
from the comp. Pulmonary arterial hypertension occurs when the blood vessels that connect the right side of the heart to the lungs constrict and raise blood pressure.
"Our immediate focus is to make Thelin commercially available in the United Kingdom and Germany, the first E.U. launch countries, with subsequent launches in other member states as government approval for reimbursement is obtained," said Bruce D. Given, Encysive president and chief executive, in a statement.
Conference call Monday . $25.00 resistance point but when that breaks $100 or more for sure. Good luck
Lerach Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit Against Encysive Pharmaceuticals Inc. Tuesday September 26, 6:16 pm ET
SAN DIEGO--(BUSINESS WIRE)--Lerach Coughlin Stoia Geller Rudman & Robbins LLP ("Lerach Coughlin") (http://www.lerachlaw.com/cases/encysive/) today announced that a class action has been commenced on behalf of an institutional investor in the United States District Court for the Southern District of Texas on behalf of purchasers of Encysive Pharmaceuticals Inc. ("Encysive") (NASDAQ:ENCY - News) publicly traded securities during the period between February 19, 2004 and March 24, 2006 (the "Class Period"). ADVERTISEMENT
If you wish to serve as lead plaintiff, you must move the Court no later than 60 days from today. If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff's counsel, William Lerach or Darren Robbins of Lerach Coughlin at 800/449-4900 or 619/231-1058, or via e-mail at wsl*lerachlaw.com. If you are a member of this class, you can view a copy of the complaint as filed or join this class action online at http://www.lerachlaw.com/cases/encysive/. Any member of the purported class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
The complaint charges Encysive and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Encysive is a biopharmaceutical company focused on the discovery, development and commercialization of different synthetic small molecule compounds for the treatment of a range of cardiovascular, vascular and related inflammatory diseases.
The complaint alleges that throughout the Class Period Encysive made false and misleading statements regarding the success of Sitaxentan, or Thelin, a drug it was developing to treat Pulmonary Arterial Hypertension ("PAH"), and stated that it had completed Phase III development of Thelin. During the Class Period, defendants led shareholders and analysts to believe that FDA approval was imminent and that such approval would make Thelin a competitor to Acetelion Ltd.'s similar drug, Tracleer (Bosentan). However, after the Company completed two successful public offerings and the individual defendants received cash/stock awards based on the apparent success of Thelin, the Company's shareholders learned that defendants had been less than forthcoming with the true prospects for Thelin. On March 27, 2006, U.S. regulators delayed approving Thelin until they could get more data. The FDA sent the Company a letter asking for information and possibly more studies to determine if Thelin was safe and effective for use in treating PAH. On this news, Encysive shares fell 49%.
Plaintiff seeks to recover damages on behalf of all purchasers of Encysive publicly traded securities during the Class Period (the "Class"). The plaintiff is represented by Lerach Coughlin, which has expertise in prosecuting investor class actions and extensive experience in actions involving financial fraud.
Lerach Coughlin, a 180-lawyer firm with offices in San Diego, San Francisco, Los Angeles, New York, Boca Raton, Washington, D.C., Houston, Philadelphia and Seattle, is active in major litigations pending in federal and state courts throughout the United States and has taken a leading role in many important actions on behalf of defrauded investors, consumers, and companies, as well as victims of human rights violations. Lerach Coughlin lawyers have been responsible for more than $20 billion in aggregate recoveries. The Lerach Coughlin Web site (http://www.lerachlaw.com) has more information about the firm.
posted
ENCY is against MYOG big time. These baseless lawsuits are just pushed nothing more. ENCYSIVE has a better start line than MYOG and that gives me confidence. FDA approval coming PAH drug is a huge market now.
posted
(approved EUROPE) $$$$$$ flowing in for next year big . Lame I dont think so FDA approval gives a good market cap of over (00000000) count your zeros. MYOG just got bought and yes that is the rerason.
posted
Financing needed for marketing..approval next, then $$$$$!!!
Press Release Source: Encysive Pharmaceuticals Inc.
Encysive Pharmaceuticals Secures Equity Financing Commitment Thursday October 19, 6:45 pm ET
HOUSTON, Oct. 19, 2006 (PRIMEZONE) -- Encysive Pharmaceuticals (NASDAQ:ENCY - News) today announced that it has secured a commitment for up to $75 million in a common stock equity financing from Azimuth Opportunity Ltd. During the 18-month term of the commitment, Encysive may sell at its sole discretion registered shares of its common stock to Azimuth at a predetermined discount to the market price. Encysive will determine the timing and amount of any sales of its stock, subject to certain conditions. Acqua Capital Management is an advisor to Azimuth Opportunity. ADVERTISEMENT
Encysive intends to use the net proceeds from any such sales of common stock for general corporate purposes, including for developing and commercializing the Company's products.
The shares are being offered pursuant to an effective registration statement filed with the Securities and Exchange Commission on June 4, 2004. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of these securities. There shall not be any sale of these securities in any state or jurisdiction where such an offer, solicitation or sale would be unlawful under the securities laws of such state or jurisdiction.
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: http://www.encysive.com.
This press release contains ``forward-looking statements'' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are our estimate of the sufficiency of our existing capital resources, our ability to raise additional capital to fund cash requirements for future operations, timelines for initiating new clinical trials, planned announcements of clinical data, the possibility of obtaining regulatory approval, our ability to manufacture and sell any products, potential drug candidates, their potential therapeutic effect, market acceptance or our ability to earn a profit from sales or licenses of any drug candidate, our ability to discover new drugs in the future, and our ability to establish future collaborative arrangements. In particular, careful consideration should be given to cautionary statements made in the various reports Encysive, including as Texas Biotechnology Corporation, has filed with the Securities and Exchange Commission. Encysive undertakes no duty to update or revise these forward-looking statements.
Contact: Encysive Pharmaceuticals Investors: Ann Tanabe, VP, Investor Relations and Corporate Communications (713) 796-8822
The Trout Group Marcy Strickler (212) 477-9007 ext. 27
Media: BMC Communications Dan Budwick (212) 477-9007 ext. 14
-------------------------------------------------------------------------------- Source: Encysive Pharmaceuticals Inc.
Email Story Set News Alert Print Story
Sponsor Results Kouefati Group - Jeans Trading, designing and manufacturing of casual wear, jeans wear and fashion wear for men, women and children with offices in Syria and Cyprus. www.kouefati.com Jim Cramer's Stock Trading Picks Get Cramer's personal portfolio, e-mail alerts sent before he trades. Try it free. www.thestreet.com TradersCue Strategies Your supermarket of trading strategies, where you can author your own fee-based service. www.traderscue.com
Related News Stories · ENCYSIVE PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement - EDGAR Online (6:03 am) · 5 More Turnaround Stocks - at Motley Fool (Thu Oct 19) · Encysive Pharmaceuticals Inc. Earnings Call scheduled for Thu, Nov 2 - CCBN (Mon Oct 16) · Encysive Pharmaceuticals Announces Conference Call to Discuss Third Quarter 2006 Results - PrimeZone Media Network (Mon Oct 16) More...
Top Stories · Stocks Fall on Caterpillar Earnings - AP (10:19 am) · Caterpillar Cuts Outlook, Shares Sink - AP (10:20 am) · Merck 3Q Net Drops 34 Pct. on Flat Sales - AP (9:44 am) · Oil Prices Rise After OPEC Decision - AP (8:57 am) More...
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
